Abstract:Biomimetic nanoparticles aim to effectively emulate the behavior of either cells or exosomes. Leukocyte-based biomimetic nanoparticles, for instance, incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here we show that, while increasing the protein:lipid ratio to a maximum of 1:20 (w/w) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. Our combined use of a microfluidic, bottom-up approach and tuning of a key synthesis parameter enabled the synthesis of reproducible, enhanced biomimetic nanoparticles that have the potential to improve the treatment of inflammatory-based conditions through targeted nanodelivery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c05792?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c05792</a>.Effect of protein buffer on NP size (Figure S1). Native protein:lipid ratio (Figure S2). NP biomimetic markers, original WB membranes, and quantification (Figure S3). CD11b orientation studies revealed equal distribution of these cytoplasmic and exoplasmic parts (Figure S4). 21-day NP storage stability studies (Figure S5). Gating strategy for flow cytometry analysis of NP uptake (Figure S6). Non-inflamed and LPS-inflamed endothelial cells (Figure S7). In vitro association and uptake of biomimetic NP by non-inflamed murine endothelial cells (Figure S8). Percentage of positive cells in singlet gate of inflamed treated cells (Figure S9). Ex vivo imaging of left and right ears for biomimetic NP targeting in a LLI model (Figure S10). TNBC tumor luminescence quantification (Figure S11). In vivo biomimetic NP liver accumulation in TNBC model (Figure S12). Ex vivo imaging of TNBC tumors for NP accumulation after 24 h (Figure S13). Intravital microscopy for NP accumulation in inflamed vasculature of TNBC mice (Figure S14). Biomimetic NP accumulation in heart, lungs, and spleen in LLI model after 8 h (Figure S15). Biomimetic NP accumulation in liver, kidneys, and blood in LLI model after 8 h (Figure S16). Biomimetic NP accumulation in heart, lungs, spleen, liver, kidneys, and blood of TNBC tumor-bearing mice after 24 h (Figure S17). Image analysis of collagen fibers workflow (Figure S18) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c05792/suppl_file/nn0c05792_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Fibroblast-Mimicking Nanodecoys for Multi-Target Antiangiogenesis in the Inflammation Treatment

Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage

Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles

Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy

Autologous Skin Fibroblast‐Based PLGA Nanoparticles for Treating Multiorgan Fibrosis

Endothelial Cell Membrane-Based Biosurface for Targeted Delivery to Acute Injury: Analysis of Leukocyte-Mediated Nanoparticle Transportation

Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy Via Blocking Vascular Endothelial Growth Factor Signaling.

An antibody-like peptidic network for anti-angiogenesis

Nano-induced Endothelial Leakiness-Reversing Nanoparticles for Targeting, Penetration and Restoration of Endothelial Cell Barrier.

Peptide-Based Nanoparticles Mimic Fibrillogenesis of Laminin in Tumor Vessels for Precise Embolization.

Cell Membrane Biomimetic Nanoparticles for Inflammation and Cancer Targeting in Drug Delivery.

Inflammatory Endothelium-Targeted and Cathepsin Responsive Nanoparticles Are Effective Against Atherosclerosis

Integrating Inflammation-Responsive Prodrug with Electrospun Nanofibers for Anti-Inflammation Application.

Sphingosine‐1‐phosphate Receptor Targeted Plga Nanobubbles for Inflammatory Vascular Endothelial Cell Catching

Suppression of Pathological Neovascularization by Anti-Flt1 Peptide Functionalized DNA Tetrahedron

Bio-intelligent plasma-engineered diferuloylmethane/fucoidan/neutrophil lysate/iron oxide nanoclusters for phototherapeutic and magnetotherapeutic with in situ magnetic gelation mitigating inflammatory diseases

Immuno-Engineered Nanodecoys for the Multi-Target Anti-Inflammatory Treatment of Autoimmune Diseases.

Adhesive nanoparticles with inflammation regulation for promoting skin flap regeneration

Legumain‐Guided Ferulate‐Peptide Self‐Assembly Enhances Macrophage‐Endotheliocyte Partnership to Promote Therapeutic Angiogenesis After Myocardial Infarction

Inflammation-Targeted Biomimetic Nano-Decoys via Inhibiting the Infiltration of Immune Cells and Effectively Delivering Glucocorticoids for Enhanced Multiple Sclerosis Treatment

Bioactive Lipid-Nanoparticles with Inherent Self-Therapeutic and Anti-Angiogenic Properties for Cancer Therapy.